Direct answer:The FDA published FY 2027 Medical Device User FeeAmendments (MDUFA) rates apply from 1 October 2026 to 30 September 2027. The FDA rate page lists the annual Establishment Regulation Fee as USD 13,785; The standard fees for common pre-market applications include $510(k) $28,653, $513 (g) $8,596, De Novo $191,020 and PMA/PDP/PMR/BLA 636,732. Enterprises that qualify as FDA Small Business Development (SBD) may apply the corresponding small business rate, with specific qualifications to be confirmed through the FDA process.The nature of the document, the current status and the enterprise’s recommendations are set out below; Specific products should be judged in the official language.
What is this file, at what stage?
The regulatory document and its status referred to in this paper is based on the original FDA page listing. The amounts vary according to the fiscal year; Exceptions, such as third-party scrutiny, apply only in prescribed circumstances and cannot be presumed on its own.
A distinction should be made between binding regulations/final rules and FDA guides, drafts, discussion papers or enforcement policies. The latter have different legal effects; Specific sources of restraint are governed by the documents and by the legislation cited.
Which enterprises and products need attention?
Equipment enterprises that plan to submit applications for 510(k), De Novo, PMA etc., as well as facilities for which annual registration fees are payable and the team responsible for payment.
It is recommended that this be confirmed on a product-business role-US market-based basis; Where product classifications or responsible subjects cannot be judged by name alone, the labels are subject to individual checks.
Where is the change from what was previously requested?
The substance of the document and the background to the previous rules are set out below. Only changes specified in official documents are considered to be changes; The recommendatory content is not to be added to the mandatory obligation.
The FDA published FY 2027 Medical Device User FeeAmendments (MDUFA) rates apply from 1 October 2026 to 30 September 2027. The FDA rate page lists the annual Establishment Regulation Fee as USD 13,785; The standard fees for common pre-market applications include $510(k) $28,653, $513 (g) $8,596, De Novo $191,020 and PMA/PDP/PMR/BLA 636,732. Enterprises that qualify as FDA Small Business Development (SBD) may apply the corresponding small business rate, with specific qualifications to be confirmed through the FDA process.
- Annual facilities registration fee:For facilities subject to registration and contribution, the subject, year and possible applicable exemption is checked in accordance with the FDA.
- Pre-market application fee:Large differences in rates for different types of applications such as 510(k), De Novo and PMA; The product path is identified before the budget is estimated.
- Small business rates:FDA Small Business Development is required to apply and qualify and cannot be used on the basis of the size of the enterprise alone.
- Services and other costs:The FDA user fees do not include the costs of consulting, testing, translating, modifying or other third-party services.
- Confirmation of type of application, date of submission of application and applicable financial year.
- Recognition of standard fees and small business fees on the FDA current rate page.
- If a small business rate is required, check SBD qualifications and valid decision number.
- Payments are completed and payment records maintained under the applicable FDA user fees system.
- Exceptions, such as confirmation of the amount, the manner of payment and the third-party review prior to submission.
Key dates and transitional arrangements
The following dates are derived from the factual summary of the documents retained here. A distinction should be made between the date of issuance, the date of closure of comments and the date of entry into force/application of the respective documents. There is no presumption in respect of matters that are not clearly stated in the original text.
- 1 October 2026: Entry into force/application of node (as expressed in the original language of the adjacent official).
- 30 September 2027: Entry into force/application of node (as expressed in the original language of the adjacent official).
The date of publication/update of the website’s articles does not correspond to the date of implementation of the statute; If the dates of the official pages differ, reference is made to the official document and the current FDA page.
How can Chinese companies prepare?
- The type of application and the financial year of receipt of the FDA are determined first; Check SBD qualifications, contributors, account numbers and timing points.
- Identify those responsible, sources and internal review nodes, and maintain official page versions and verification dates.
- If the official document is revised, withdrawn or the final version issued, the applicable conclusions are reassessed and the records updated.
For this purpose, the recommendation does not substitute for the obligation set out in the body of the statute.
Exceptions, pending confirmations and common misreading
- The amounts vary according to the fiscal year; Exceptions, such as third-party scrutiny, apply only in prescribed circumstances and cannot be presumed on its own.
- When exemptions, transition periods, border products or different business actors are encountered, the original text should be consulted on the basis of specific facts; Uncertainties should be clearly identified for confirmation.
- Registration, listing, submission or obtaining of a reply should not be mistakenly referred to as FDA approval or authentication.
Official information and reconciliation records
- FDA:Medical Device User Fee Amendments (MDUFA): Fees
- FDA:Medical Device User Fees
- FDA:Small Business Determination Program
(b) The station’s author: Mr. Toshito. Reviewer: Mr. Toto. Date of the structural review of the article: 2026-11-02; The statutory status and specific obligations are based on the official language listed.
Next
Identification of scope of application by product and corporate role, viewing Regulatory UpdatesAnd the corresponding FDA Compliance Service Scope; If you need a case judgement, you can do it. Contact PageSubmission of product information.